key: cord-0934924-1syadjvm
authors: Jaime‐Pérez, José Carlos; González‐Treviño, Mariana; Meléndez‐Flores, Jesús D.; Ramos‐Dávila, Eugenia M.; Colunga‐Pedraza, Julia E.; Colunga‐Pedraza, Perla R.; Jiménez‐Antolinez, Valentine; Gómez‐Almaguer, David
title: Safety and feasibility of outpatient hematopoietic cell transplantation in pediatric patients during the COVID‐19 pandemic: A single‐center experience
date: 2021-07-22
journal: Pediatr Blood Cancer
DOI: 10.1002/pbc.29252
sha: 08d8263b85da2ca6871063852d3c38ce2e3a6612
doc_id: 934924
cord_uid: 1syadjvm

nan

To the Editor:

Hematopoietic cell transplantation (HCT) represents a potentially curative treatment for children with high-risk hematological malignancies, and pediatric patients typically require hospitalization to undergo HCT. 1 The recent COVID-19 pandemic has raised concerns regarding HCT in an inpatient setting, considering that nosocomial outbreaks of COVID-19 have been reported in hematological wards, 2,3 and HCT recipients are admitted to a general hospital ward in centers without a conventional HCT unit, where the limited trained nurse personnel are shared within patients. Thus, ambulatory HCT rises as a possible approach in this situation. 4, 5 Our hematology unit has more than 20 years of experience conducting HCTs in an outpatient setting in adults. 6, 7 We report the pediatric outpatient HCT-related outcomes during the COVID-19 pandemic (March-December 2020) at a referral center providing care for the general, open-population in Northeast Mexico. The study protocol was approved by the ethics and research committees.

All legal guardians signed informed consent before any procedure.

The standard pediatric HCT protocol remained unaffected, except for the implementation of an outpatient approach. HCTs were categorized as inpatient if the stem cell infusion occurred while admitted to the hospital and outpatient if both the conditioning regimen and stem cell infusion were administered in the outpatient clinic. Eligibility for outpatient HCT included children with a Lansky score ≥70%, an adequate venous access and normal cardiac and renal function, temporary residence near the hospital (≤1 hour of travel distance), and an adequate caregiver.

The conditioning regimen for allogeneic-HCT consisted of 3 days of fludarabine 25 mg/m 2 /day and cyclophosphamide 350 mg/m 2 /day, and melphalan 70-100 mg/m 2 for 2 days with or without 2 Gy of total body irradiation and antithymocyte globulin in aplastic anemia. Graftversus-host disease (GVHD) prophylaxis included cyclophosphamide 50 mg/kg/day for 2 days (+3 and +4), mycophenolic acid 2 g/day from day +5 to day +35, and oral cyclosporine 6 m/kg/day from day +5, adjusted to 150-300 ng/ml and tapered between day +100 and day +180. For autologous transplants, the regimen varied according to diagnosis. Pediatric disease-risk index (DRI) was calculated for malignant diseases. 8 Table 1 . Table S1 . Studies have shown a mild course of COVID-19 in the general pediatric population. 11 In our cohort, four patients developed COVID-19 after HCT; the two patients that belonged to the inpatient group had a severe course requiring advanced care and subsequently died of the disease. These outcomes could be attributed to their high-risk baseline characteristics. In contrast, the two patients from the outpatient group presented a mild course, consequence of a better clinical status, compatible to previous reports. 12, 13 There are several practical considerations when performing HCT in an outpatient pediatric setting, including ensuring adequate isolation measures of patients and their caregivers, achieving an appropriate hydration when using post-HCT cyclophosphamide, or during mucositis due to alkylator agents, and difficulty in assessing proper central line care at home.

In conclusion, our results demonstrate the importance of continuing to perform HCTs in pediatric patients despite the outbreak, because an outpatient approach can help reduce exposure to SARS-CoV-2 and avoid irreversible disease progression.

Pediatric hematopoietic stem cell transplant

Nosocomial outbreak of COVID-19 in a hematologic ward

Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit -high mortality rate in infected patients with haematologic malignancies

Impact of COVID-19 pandemic on

Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America

Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country

Outpatient haploidentical stem cell transplantation using posttransplant cyclophosphamide is safe and feasible

A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation

Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors

Pediatric transplantation in Europe during the COVID-19 pandemic: early impact on activity and healthcare

Children with Covid-19 in pediatric emergency departments in Italy

Benign course of SARS-CoV-2 infection in a series of pediatric oncology patients

Coronavirus disease 2019 3 months after hematopoietic stem cell transplant: a pediatric case report

The authors declare that there is no conflict of interest.José Carlos Jaime-Pérez